The Challenge of High BMI and Insulin Absorption

IMPORTANT SAFETY INFORMATION FOR APIDRA^®

Apidra^® is a rapid-acting human insulin analog indicated to improve glycemic control in adults with type 2 diabetes or adults and children (4 years and older) with type 1 diabetes. Apidra^® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to Apidra^® or any of its excipients. Apidra^® should normally be used in regimens that include a longer-acting insulin.

OptiClik^® is a reusable insulin delivery device for use with a 3-mL Apidra^® cartridge (U-100). Needles, OptiClik^® and cartridge systems must not be shared.

Apidra^® has a more rapid onset and shorter duration of action than regular human insulin. When used as a mealtime insulin, the dose of Apidra^® should be given within 15 minutes before or within 20 minutes after starting a meal. Glucose monitoring is essential for patients receiving insulin therapy. Any change in insulin and/or regimen should be made cautiously, only under medical supervision, and may require a change in dose. Concomitant oral antidiabetic treatment may need to be adjusted. As with all insulin preparations, the time course of Apidra^® action may vary by individual or at different times in the same individual and depends on injection site, blood supply, temperature, and level of physical activity.

Hypoglycemia is the most common adverse reaction of insulin therapy, including Apidra^®. The timing of hypoglycemia usually reflects the time-action profile of the administered insulin formulations. Other adverse events associated with Apidra^® include hypokalemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, and rash. Less common, but potentially more serious or life-threatening, is generalized allergy to insulin, including anaphylactic reactions.

Apidra^® should not be mixed with other insulins or with a diluent when used in the pump.